|
Symbol
|
AWSBIL | ZYALTQ | SKS4LK | OVCRCH | OZTRCH | Z0A4JZ | AANOTQ | ABVHSQ | AYSBIL | LXORLK | Z0ATYZ | CQWBKB | ACDQTQ | RMAKRV | RMAG0V | Z0B7EZ | UJERWU | LZPRCH | RMBGJV | RMBU5V |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nom | Multi Reverse Convertible | Multi Reverse Convertible | LUKB Softcallable Multi Reverse Convertible | Worst of Callable Reverse Convertible | Worst of Callable Reverse Convertible | Autocallable Reverse Convertible Defensive worst | Multi Reverse Convertible | Multi Reverse Convertible | Reverse Convertible | LUKB Multi Reverse Convertible | Autocallable Reverse Convertible Defensive worst | Reverse Convertible | Multi Reverse Convertible | Autocallable Multi Vonti | Autocallable Multi Vonti | Autocallable Reverse Convertible Defensive worst | GOAL | Worst of Callable Reverse Convertible | Multi Vonti | Multi Vonti |
|
Sous-jacent
|
Compagnie Financière Richemont SA / Logitech International SA / Sika AG / Straumann Hldg. AG | Givaudan / Sonova Hldg. AG / Straumann Hldg. AG | Julius Baer Group / Roche AG / Straumann Hldg. AG | Novartis AG / Sandoz Group AG / Straumann Hldg. AG | Kühne & Nagel Intl. AG / Straumann Hldg. AG / VAT Group | ABB / Holcim/Amrize Basket / Straumann Hldg. AG | Adecco Group AG / OC Oerlikon N / Straumann Hldg. AG / VAT Group | Sika AG / Helvetia Baloise Holding AG / Straumann Hldg. AG / Sandoz Group AG | Alcon / Sonova Hldg. AG / Straumann Hldg. AG / Ypsomed Hldg. AG | Givaudan / Julius Baer Group / Straumann Hldg. AG | Alcon / Novartis AG / Sandoz Group AG / Straumann Hldg. AG | Lonza Group N / Novartis N / Roche GS / Straumann Hldg. AG | Adecco Group AG / Logitech International SA / Stadler Rail AG / Straumann Hldg. AG / UBS Group AG | Lonza Group N / Sika AG / Straumann Hldg. AG | Lonza Group N / Sika AG / Straumann Hldg. AG | Alcon / Straumann Hldg. AG / Ypsomed Hldg. AG | Bachem Hldg. AG / Lonza Group N / Straumann Hldg. AG | SGS S.A. Ltd. / Sika AG / Straumann Hldg. AG | Alcon / Lonza Group N / Novartis AG / Straumann Hldg. AG | Lonza Group N / Novartis AG / Straumann Hldg. AG / Ypsomed Hldg. AG |
|
Emetteur
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Échéance
|
23.10.2026 | 02.11.2026 | 10.07.2026 | 09.06.2026 | 07.04.2026 | 30.03.2026 | 27.09.2029 | 07.10.2026 | 22.04.2027 | 05.03.2027 | 05.03.2027 | 13.03.2028 | 21.03.2030 | 24.06.2026 | 24.06.2026 | 10.12.2026 | 02.08.2027 | 07.08.2029 | 19.08.2027 | 22.02.2027 |
| Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Prix d'exercise
|
37,8352 | 2 733,78 | 39,21 | 76,59 | 301,07 | 100,793 | 2,8795 | 90,285 | 283,15 | 2 812,194 | 31,4067 | 200,5388 | 18,434 | 441,20 | 419,30 | 81,90 | 51,2961 | 150,75 | 51,80 | 292,70 |
| rendement max. p.a. | 7,98% | 16,76% | 11,18% | 18,36% | 31,91% | 37,68% | 12,75% | 23,86% | 19,18% | 11,69% | 17,80% | 7,28% | 9,22% | 40,55% | 30,59% | 18,71% | 10,16% | 7,24% | 8,06% | 10,78% |
| Demande | - | 91,15 | - | - | 93,38 | - | - | 87,05 | - | - | - | 95,02 | 85,59 | 86,30 | 90,10 | - | 93,00 | - | 96,60 | 92,80 |
| Offre | - | 91,95 | - | - | 94,18 | - | - | 87,85 | - | - | - | 95,82 | 86,39 | 87,30 | 91,10 | - | 94,00 | - | 97,40 | 93,80 |